Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsGoodwillGoodwill & IntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

United Therapeutics (UTHR) Inventory (2016 - 2025)

United Therapeutics' Inventory history spans 17 years, with the latest figure at $183.1 million for Q4 2025.

  • For Q4 2025, Inventory rose 15.96% year-over-year to $183.1 million; the TTM value through Dec 2025 reached $183.1 million, up 15.96%, while the annual FY2025 figure was $183.1 million, 15.96% up from the prior year.
  • Inventory for Q4 2025 was $183.1 million at United Therapeutics, up from $176.5 million in the prior quarter.
  • Across five years, Inventory topped out at $183.1 million in Q4 2025 and bottomed at $88.2 million in Q1 2022.
  • The 5-year median for Inventory is $103.8 million (2023), against an average of $121.1 million.
  • The largest annual shift saw Inventory decreased 5.89% in 2022 before it surged 41.23% in 2024.
  • A 5-year view of Inventory shows it stood at $93.8 million in 2021, then grew by 8.74% to $102.0 million in 2022, then rose by 9.61% to $111.8 million in 2023, then soared by 41.23% to $157.9 million in 2024, then rose by 15.96% to $183.1 million in 2025.
  • Per Business Quant, the three most recent readings for UTHR's Inventory are $183.1 million (Q4 2025), $176.5 million (Q3 2025), and $169.2 million (Q2 2025).